Drug Type Bispecific antibody |
Synonyms + [1] |
Target |
Mechanism 4-1BB inhibitors(Tumor necrosis factor receptor superfamily member 9 inhibitors), HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HER2 Positive Solid Tumors | Phase 2 | KR | 26 Aug 2022 | |
HER2 Positive Solid Tumors | Phase 2 | AU | 26 Aug 2022 | |
Metastatic Solid Tumor | Phase 2 | AU | 26 Aug 2022 | |
Metastatic Solid Tumor | Phase 2 | KR | 26 Aug 2022 | |
Stomach Cancer | Phase 1 | AU | - |